Diagnostic Usefulness of Genomic Breakpoint Analysis of Various Gene Rearrangements in Acute Leukemias: A Perspective of Long Distance– or Long Distance Inverse-PCR–based Approaches

John Jeongseok Yang, M.D.¹, Rolf Marschalek, Ph.D.³, Claus Meyer, Ph.D.³, and Tae Sung Park, M.D.²

Department of Medicine¹, Graduate School, Kyung Hee University, Seoul; Department of Laboratory Medicine², Kyung Hee University School of Medicine, Seoul, Korea; Institute of Pharmaceutical Biology³, ZAFES, Diagnostic Center of Acute Leukemia, Goethe-University of Frankfurt, Biocenter, Frankfurt/Main, Germany

The discovery of the 46 human chromosomes by Tijo and Levan in 1956 is one of the most remarkable discoveries of the century, thus defining the starting point of conventional cytogenetics [1]. After the Philadelphia chromosome was found by Nowell and Hungerford in 1960, Rowley identified several major chromosomal translocations in human leukemias in the 1970s, including t(8;21), t(15;17) and t(9;22) [2]. By the middle of 1980s, the Philadelphia chromosome, defined at the chromosome level, was finally identified as originating from BCR-ABL1 rearrangement. In the following molecular biology era that was guided by passionate researchers and their contributions, many genetic aberrations known at the chromosomal level were revealed to be associated with gene fusions such as PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11, and MLL-AF4. Therefore, it can be said that from the inception of the field of cancer cytogenetics and for nearly half a century, chromosomal translocations or gene rearrangements have been the main research focus. However, efforts to search for second hit genetic aberrations were made throughout the recent decades with the aid of remarkable technical advancements such as high throughput sequencing technologies, which led to increased interest in gene mutations. Furthermore, recent discoveries related to gene expression profiles, the identification of disease-specific gene signatures, epigenetic mechanisms, and the role of microRNA in acute leukemias are filling in this emerging genetic picture [3].

The current molecular diagnostic approach for leukemias in Korea is mainly focused on identifying chromosomal translocations or gene rearrangements by 3 different technologies: 1) conventional cytogenetics, 2) FISH analysis using particular probe sets, and 3) specific reverse transcriptase-PCR (RT-PCR) assays. All of these methods are useful for detecting known gene rearrangements such as the MLL gene translocations, although each method has its own merits and disadvantages. Conventional cytogenetic analysis has the advantage being able to evaluate the number and integrity of chromosomes. Moreover, it has the potential to indicate certain chromosome abnormalities. However, it is quite difficult to detect cryptic gene rearrangements of submicroscopic deletions or inversions with conventional cytogenetic analysis. Both split-signal FISH technologies and RT-PCR assays have the advantage of being fast and target gene-specific. However, commonly employed multiplex RT-PCR kits such as “HemaVision” (DNA Technology, Aarhus, Denmark) are also limited in the number of rearrangements they can detect [4, 5]. For example, if an 11q23 abnormality is...
suspected by chromosome analysis, an MLL rearrangement can be detected by split-signal FISH without knowledge of the partner genes involved. Therefore, both of these technologies (RT-PCR and split-signal FISH) will not allow the detection of currently unknown MLL rearrangements, as further studies are required to identify the actual partner genes. In this letter, we would like to introduce an alternative, compensatory diagnostic method, termed long distance-PCR (LD-PCR) or long distance inverse-PCR (LDI-PCR), which can be used in combination with the current molecular diagnostic tools.

As previously described, LDI-PCR is a modified LD-PCR method that utilizes genomic DNA [6-8]. Briefly, the DNA sample is treated and analyzed as previously described [6, 7]. First, 1 μg of genomic DNA is digested with restriction enzymes and re-ligated to form circular DNA before performing LDI-PCR using myeloid/lymphoid leukemia (MLL)-specific primers. Then, restriction polymorphic PCR amplimers are isolated from the gel and subjected to DNA sequence analysis to obtain patient-specific fusion sequences. Detailed LDI-PCR methods were previously provided elsewhere [6, 7].

By applying this technique, we have successfully identified the MLL-CASP8AP2 rearrangement in a Korean AML patient, as well as MLL-related 3-way and 4-way translocations using precise genomic breakpoint analysis of LDI-PCR, with additional findings regarding the involvement of the NRXN1 and CCDC6 genes in fusion breakpoints [9-12]. Thus, this technique seems to have several advantages over the currently established diagnostic procedures (Fig. 1). The combined use of these previously described techniques allows for routine diagnostic work to be completed more quickly, while aiding researchers in making novel discoveries.

Importantly, LD-PCR is useful for recognizing unusual cryptic cytogenetic findings or discrepancies in molecular results that are hard to identify through common molecular diagnostic methods. A cryptic PML-RARA rearrangement in acute promyelocytic leukemia (APL) patient and another unique case of PML-AD-AMTS17-RARA rearrangement in APL were identified by using LD-PCR [13, 14]. The molecular identification of a PML-RARA genomic fusion breakpoint using genomic DNA from the PML-RARA FISH-negative cell pellet was a representative example of the utility of this method [13]. Of note, gene rearrangements with alternative splicing (such as variant PML-RARA and CBFB-MYH11) are indicated for applying multiplex LD- or LDI-PCR.

Lastly, we have applied LD-PCR to the clonal eosinophilic disorder, which was first introduced in the 2008 WHO classification, for discovery of the genomic fusion breakpoint of ZMYM2-FGFR1 rearrangement [15]. This method was particularly useful as FGFR1-rearrangement has multiple fusion partner genes such as MLL rearrangement and cDNA was not available in this lymphoma case, suggesting that future utilization of LD-PCR as a method of choice for such circumstances is possible. However, PCR-based analyses of genomic DNA are not always feasible, as large intron size can be a limitation for applying LD-PCR. Further studies aimed at the usage of multiplex procedures based on LD- or LDI-PCR techniques will unveil the potential for this analysis in new disease states, such as in solid tumor DNA samples, for example [16, 17]. Furthermore, using the established sequences of genomic fusion sites for patient-specific minimal residual disease monitoring of acute leukemia has also been reported [7, 18].

LD- and LDI-PCR are supplementary methods that overcome the limitations of conventional cytogenetics, FISH, and RT-PCR, and exactly how to introduce this new technology into routine diagnostic procedures should be discussed among laboratory physicians in the field of hematology in Korea. Cutting edge methods derived from advanced molecular technologies in the field of genomics such as whole genome/exome sequencing or microarray are important, but are also expensive. LD- and LDI-PCR are relatively inexpensive procedures that complement the existing routine methods. We hope that these advanced diagnostic methods will eventually be adopted as tailored, target-specific genomic analyses in the near future.
Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Acknowledgements

This research study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Education, Science and Technology (2011-0026054), and also by grant number 107819 from Deutsche Krebshilfe (German Cancer Aid).

REFERENCES

1. Tijo JH and Levan A. The chromosome number of man. Hereditas 1956; 42:1-6.
2. Rowley JD. Chromosomal translocations; revisited yet again. Blood 2008; 112:2183-9.
3. Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010;10:23-36.
4. Choi HJ, Kim HR, Shin MG, Kook H, Kim HJ, Shin JH, et al. Spectra of chromosomal aberrations in 325 leukemia patients and implications for the development of new molecular detection systems. J Korean Med Sci 2011;26:886-92.
5. Kim MJ, Choi JR, Suh JT, Lee HJ, Lee WI, Park TS. Diagnostic standardization of leukemia fusion gene detection system using multiplex reverse transcriptase-polymerase chain reaction in Korea. J Korean Med Sci 2011;26:1390-400.
6. Meyer C, Schneider B, Reichel M, Angermueller S, Strehi S, Schnittger S, et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA 2005;102:449-54.
7. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009; 23:1490-9.
8. Lee SG, Park TS, Oh SH, Park JC, Yang YJ, Marschalek R, et al. De novo acute myeloid leukemia associated with t(11; 17)(q23;q25) and MLL-SEPT9 rearrangement in an elderly patient: a case study and review of the literature. Acta Haematol 2011;126:195-8.
9. Park TS, Lee ST, Song J, Lee KA, Lee SG, Kim J, et al. MLL rearrangement with t(6;11)(q15;q23) as a sole abnormality in a patient with de novo acute myeloid leukemia: conventional cytogenticstics, FISH, and multicolor FISH analyses for detection of rare MLL-related chromosome abnormalities. Cancer Genet Cytogenet 2008;187:50-3.
10. Park TS, Lee SG, Song J, Lee KA, Kim J, Choi JR, et al. CASP8AP2 is a novel partner gene of MLL rearrangement with t(6;11)(q15;q23) in acute myeloid leukemia. Cancer Genet Cytogenet 2009;195:94-5.
11. Lee SG, Park TS, Won SC, Song J, Lee KA, Choi JR, et al. Three-way translocation involving MLL, MLLT1, and a novel third partner, NRXN1, in a patient with acute lymphoblastic leukemia and t(2;19;11)(p12;p13.3; q23). Cancer Genet Cytogenet 2010;197:32-8.
12. Cho SY, Park TS, Oh SH, Cho EH, Oh D, Huh JY, et al. Genomic analysis of a four-way t(4;11;22;10) associated with MLL-AF4 in an adult acute lymphoblastic leukemia. Ann Hematol 2012;91:977-9.
13. Kim MJ, Cho SY, Kim MH, Lee JJ, Kang SY, Cho EH, et al. FISH-negative cryptic PML-RARA rearrangement detected by long-distance polymerase chain reaction and sequencing analyses: a case study and review of the literature. Cancer Genet Cytogenet 2010;203:278-83.
14. Lim G, Cho EH, Cho SY, Shin SY, Park JC, Yang YJ, et al. A novel PML-ADAMTS17-RARA gene rearrangement in a patient with pregnancy-related acute promyelocytic leukemia. Leuk Res 2011;35:e106-10.
15. Yang JJ, Park TS, Choi JR, Park SJ, Cho SY, Jun KR, et al. Submicroscopic deletion of FGFR1 gene is recurrently detected in myeloid and lymphoid neoplasms associated with ZMYM2-FGFR1 rearrangements: a case study. Acta Haematol 2012;127:119-23.
16. Meyer C, Brieger A, Plotz G, Weber N, Passmann S, Dingermann T, et al. An interstitial deletion at 3p21.3 results in the genetic fusion of MLH1 and ITGA9 in a Lynch syndrome family. Clin Cancer Res 2009;15:762-9.
17. Cie H, Meyer C, Herr R, Janzakir WG, Lambert S, Jones DT, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011;121:763-74.
18. Burmeister T, Marschalek R, Schneider B, Meyer C, Gokbuget N, Schwartz S, et al. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia 2006;20:451-7.